Share on LinkedInShare on LinkedIn

ARTICLE · 05 APRIL 2018

New Use Patent For Janssen's REMICADE Valid And Infringed By Hospira's Biosimilar INFLECTRA

Infliximab is an antibody that inhibits binding at TNF-α receptors, a key target in autoimmune diseases.

CanadaIntellectual Property

On March 7, 2018, the Federal Court upheld the validity of Kennedy's patent for a use of infliximab (Janssen's REMICADE) (Patent No. 2,261,630 [the "630 patent"]), and granted Kennedy's counterclaim that Hospira's biosimilar INFLECTRA infringed the 630 patent: Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2018 FC 259. 

Infliximab is an antibody that inhibits binding at TNF-α receptors, a key target in autoimmune diseases. Janssen's infliximab product, REMICADE, is approved for use in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA).  In broad terms the 630 patent claims use of the combination of infliximab with MTX for the treatment of RA in patients whose disease was not controlled by previous MTX treatment alone.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from